血浆趋化因子早期预测免疫治疗肺癌患者放射性肺炎
这项多中心前瞻性研究纳入2021至2023年接受胸部放疗的肺癌患者214例,其中既往免疫检查点抑制剂治疗者71例。既往免疫治疗者症状性放射性肺炎发生率更高,放疗前及放疗2周、4周血浆CXCL10与放射性肺炎显著相关。整合CXCL10、CXCL14、CXCL2与平均肺剂量的风险评分预测性能优于单一因素,曲线下面积0.757。
要点
- 既往免疫治疗者症状性放射性肺炎发生率为45.07%,高于未接受者。
- 放疗前及放疗2周、4周血浆CXCL10均与症状性放射性肺炎显著相关。
- 整合趋化因子与平均肺剂量的风险评分曲线下面积为0.757。
核心结论
- 在这项前瞻性研究中,血浆趋化因子可预测既往接受免疫治疗的肺癌患者未来发生症状性放射性肺炎的风险。
- 尽管曲线下面积中等,基于血浆趋化因子和平均肺剂量的评分系统是预测症状性放射性肺炎的可行工具,有助于为患者制定个性化和最佳治疗。
研究设计与样本
- 多中心前瞻性研究,纳入2021至2023年接受胸部放疗的肺癌患者,共214例。
- 采用Luminex法检测血浆细胞因子,用Cox比例风险模型识别放射性肺炎的风险因素和生物标志物。
- 采用Fine-Gray竞争风险分析进行敏感性分析,用受试者工作特征曲线评估细胞因子的预测价值。
主要发现
- 214例接受胸部放疗的患者中,75例(35.05%)发生症状性放射性肺炎。
- 71例既往接受免疫检查点抑制剂治疗的患者中,32例(45.07%)发生症状性放射性肺炎。
- 既往免疫检查点抑制剂治疗者症状性放射性肺炎发生率和血浆趋化因子水平均高于未接受者。
- 既往免疫治疗患者中,放疗前血浆CXCL10(HR 1.29;95%CI 1.03-1.61)、放疗2周时(HR 1.28;95%CI 1.03-1.59)和放疗4周时(HR 1.65;95%CI 1.19-2.28)与放射性肺炎显著相关。
- 放疗前、放疗2周和放疗4周血浆CXCL10的曲线下面积分别为0.625、0.680和0.679;整合CXCL10、CXCL14、CXCL2和平均肺剂量的风险评分曲线下面积为0.757,优于单一因素。
关键数值与推荐
- 既往免疫治疗患者放疗前血浆CXCL10的HR为1.29(95%CI 1.03-1.61)。
- 既往免疫治疗患者放疗2周时血浆CXCL10的HR为1.28(95%CI 1.03-1.59)。
- 既往免疫治疗患者放疗4周时血浆CXCL10的HR为1.65(95%CI 1.19-2.28)。
- 放疗前、放疗2周和放疗4周血浆CXCL10的曲线下面积分别为0.625、0.680和0.679。
- 整合CXCL10、CXCL14、CXCL2和平均肺剂量的风险评分曲线下面积为0.757。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study is aimed to identify biomarkers for symptomatic radiation pneumonitis (RP) in patients with lung cancer treated with immune checkpoint inhibitors (ICIs). METHODS AND MATERIALS: This multicenter, prospective study enrolled patients with lung cancer receiving thoracic radiation therapy (RT) between 2021 and 2023. Plasma cytokines were measured using Luminex assays. Cox proportional hazards model was used to identify risk factors and biomarkers for RP. Sensitivity analysis was conducted using Fine-Gray competing risk analyses. Receiver operating characteristic curves were used to assess the predictive value of the cytokines. RESULTS: A total of 214 patients receiving thoracic RT were included in this study, with 75 (35.05%) patients experiencing symptomatic RP. Among the 71 patients with prior ICI treatment, 32 (45.07%) developed symptomatic RP. Patients with prior ICI treatment had higher incidence of symptomatic RP and plasma chemokines than those without prior ICI treatment. For patients with prior ICI treatment, plasma CXCL10 before RT (hazard ratio [HR], 1.29; 95% CI, 1.03-1.61) and at 2 weeks (HR, 1.28; 95% CI, 1.03-1.59) and 4 weeks during RT (HR, 1.65; 95% CI, 1.19-2.28) were significantly associated with RP. The area under the curves (AUC) of plasma CXCL10 at baseline, 2 weeks and 4 weeks during RT were 0.625, 0.680, and 0.679, respectively. Plasma CXCL14 before RT and CXCL2 during RT were also predictors of RP. A risk score integrating CXCL10, CXCL14, CXCL2, and mean lung dose showed better predictive performance than individual factors (AUC = 0.757). CONCLUSIONS: In this prospective study, plasma chemokines predict future risk of symptomatic RP in patients with lung cancer who have received prior immunotherapy. Despite with moderate AUC, the scoring system based on plasma chemokines and mean lung dose is a feasible tool for predicting symptomatic RP, aiding in tailoring personalized and optimal treatment for patients.
引用
- Xiao L, Li Y, Wang S, et al. Early Prediction of Radiation Pneumonitis in Patients With Lung Cancer Treated With Immunotherapy Through Monitoring of Plasma Chemokines. Int J Radiat Oncol Biol Phys. 2025. PMID: 39993540. doi:10.1016/j.ijrobp.2025.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。